2 completed, 2 recruiting, 2 unknown, 1 terminated. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Unknown 2, Completed 1 |
Follow Fundacion Oncosur: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule - Metastatic Prostate Cancer | Phase 2 | Recruiting | Fundacion Oncosur | 78 | 2024-07-05 | 2026-10-05 |
| Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) Pembrolizumab, Carboplatin, Cabazitaxel - Prostate Cancer Metastatic | Phase 2 | Recruiting | Fundacion Oncosur | 42 | 2023-05-05 | 2024-06-11 |
| Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer Combination, Palbociclib + Binimetinib - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | Fundacion Oncosur | 24 | 2020-11-18 | 2025-03-24 |
| Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) Atezolizumab, BCG - Invasive Bladder Cancer | Phase 1 | Unknown | Fundacion Oncosur | 40 | 2020-02-03 | 2024-05-21 |
| Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. PM 01183, Atezolizumab - Carcinoma, Small Cell Lung | Phase 1 / Phase 2 | Unknown | Fundacion Oncosur | 184 | 2019-12-13 | 2023-11-18 |
| Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer Cabozantinib - Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma Stage IV | Phase 2 | Terminated | Fundacion Oncosur | 18 | 2018-11-01 | 2024-04-26 |
| Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer Paclitaxel 80 mg/m2, Nab-paclitaxel 100 mg/m2 days 1, 8 and 15, Nab-paclitaxel 150 mg/m2 days 1, 8 and 15 - Breast Cancer | Phase 2 | Completed | Fundacion Oncosur | 60 | 2012-12-01 | 2016-03-29 |
Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Neurotoxicity Syndromes (1) · Prostatic Diseases (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
atezolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · PM 01183 (1) · Paclitaxel (1) · binimetinib (1) · cabazitaxel (1) · cabozantinib (1) · enzalutamide (1) · palbociclib (1) · pembrolizumab (1) · talazoparib (1)
Spain (7) · France (1)
Albert Font Pous, Dr (1) · Blanca Cantos, MD (1) · Daniel Castellano, MD (1) · David Olmos, Dr. (1) · Elena Castro, Dra. (1) · Enrique Gonzalez-Billalabeitia, Dr (1) · Eva Ciruelos, MD (1) · Guillermo de Velasco, MD PhD (1) · Javier Puente, Dr (1) · Juan A Guerra, MD (1)
2019 (1), 2023 (1)